Biosig Technologies (STEX) Competitors

$1.34 +0.21 (+18.14%)

As of 02:41 PM Eastern

STEX vs. SIBN, CBLL, BWAY, MDXG, and NPCE

Should you buy Biosig Technologies stock or one of its competitors? MarketBeat compares Biosig Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biosig Technologies include SiBone (SIBN), CeriBell (CBLL), Brainsway (BWAY), MiMedx Group (MDXG), and NeuroPace (NPCE). These companies are all part of the "medical equipment" industry.

How does Biosig Technologies compare to SiBone?

Biosig Technologies (NASDAQ:STEX) and SiBone (NASDAQ:SIBN) are both small-cap medical equipment companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

Biosig Technologies has a beta of 1.58, meaning that its share price is 58% more volatile than the broader market. Comparatively, SiBone has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market.

SiBone has higher revenue and earnings than Biosig Technologies. SiBone is trading at a lower price-to-earnings ratio than Biosig Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	N/A	N/A	-$462.77M	-$9.71	N/A
SiBone	$200.93M	3.25	-$18.90M	-$0.39	N/A

In the previous week, Biosig Technologies had 2 more articles in the media than SiBone. MarketBeat recorded 6 mentions for Biosig Technologies and 4 mentions for SiBone. Biosig Technologies' average media sentiment score of 0.34 beat SiBone's score of -0.22 indicating that Biosig Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biosig Technologies	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SiBone	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Biosig Technologies has a net margin of 0.00% compared to SiBone's net margin of -8.10%. SiBone's return on equity of -9.56% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	-717.92%	-336.75%
SiBone	-8.10%	-9.56%	-7.06%

7.2% of Biosig Technologies shares are held by institutional investors. Comparatively, 98.1% of SiBone shares are held by institutional investors. 52.7% of Biosig Technologies shares are held by company insiders. Comparatively, 4.0% of SiBone shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Biosig Technologies currently has a consensus price target of $8.00, suggesting a potential upside of 499.25%. SiBone has a consensus price target of $23.00, suggesting a potential upside of 56.15%. Given Biosig Technologies' higher probable upside, equities analysts plainly believe Biosig Technologies is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

SiBone beats Biosig Technologies on 8 of the 15 factors compared between the two stocks.

How does Biosig Technologies compare to CeriBell?

Biosig Technologies (NASDAQ:STEX) and CeriBell (NASDAQ:CBLL) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings.

Biosig Technologies has a net margin of 0.00% compared to CeriBell's net margin of -63.51%. CeriBell's return on equity of -38.19% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	-717.92%	-336.75%
CeriBell	-63.51%	-38.19%	-30.92%

Biosig Technologies presently has a consensus price target of $8.00, suggesting a potential upside of 499.25%. CeriBell has a consensus price target of $22.20, suggesting a potential upside of 17.98%. Given Biosig Technologies' higher possible upside, equities analysts plainly believe Biosig Technologies is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

CeriBell has higher revenue and earnings than Biosig Technologies. CeriBell is trading at a lower price-to-earnings ratio than Biosig Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	N/A	N/A	-$462.77M	-$9.71	N/A
CeriBell	$89.06M	8.02	-$53.41M	-$1.63	N/A

Biosig Technologies has a beta of 1.58, suggesting that its share price is 58% more volatile than the broader market. Comparatively, CeriBell has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market.

In the previous week, Biosig Technologies had 3 more articles in the media than CeriBell. MarketBeat recorded 6 mentions for Biosig Technologies and 3 mentions for CeriBell. CeriBell's average media sentiment score of 0.57 beat Biosig Technologies' score of 0.34 indicating that CeriBell is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biosig Technologies	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CeriBell	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

7.2% of Biosig Technologies shares are owned by institutional investors. 52.7% of Biosig Technologies shares are owned by company insiders. Comparatively, 20.1% of CeriBell shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

CeriBell beats Biosig Technologies on 9 of the 16 factors compared between the two stocks.

How does Biosig Technologies compare to Brainsway?

Biosig Technologies (NASDAQ:STEX) and Brainsway (NASDAQ:BWAY) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

Biosig Technologies has a beta of 1.58, suggesting that its share price is 58% more volatile than the broader market. Comparatively, Brainsway has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market.

In the previous week, Biosig Technologies had 4 more articles in the media than Brainsway. MarketBeat recorded 6 mentions for Biosig Technologies and 2 mentions for Brainsway. Biosig Technologies' average media sentiment score of 0.34 beat Brainsway's score of 0.00 indicating that Biosig Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biosig Technologies	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Brainsway	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Brainsway has a net margin of 15.68% compared to Biosig Technologies' net margin of 0.00%. Brainsway's return on equity of 12.28% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	-717.92%	-336.75%
Brainsway	15.68%	12.28%	7.75%

Brainsway has higher revenue and earnings than Biosig Technologies. Biosig Technologies is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	N/A	N/A	-$462.77M	-$9.71	N/A
Brainsway	$52.22M	11.69	$7.57M	$0.35	43.57

Biosig Technologies presently has a consensus target price of $8.00, indicating a potential upside of 499.25%. Brainsway has a consensus target price of $15.00, indicating a potential downside of 1.64%. Given Biosig Technologies' higher probable upside, equities research analysts plainly believe Biosig Technologies is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Brainsway	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

7.2% of Biosig Technologies shares are held by institutional investors. Comparatively, 30.1% of Brainsway shares are held by institutional investors. 52.7% of Biosig Technologies shares are held by insiders. Comparatively, 19.0% of Brainsway shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Brainsway beats Biosig Technologies on 10 of the 15 factors compared between the two stocks.

How does Biosig Technologies compare to MiMedx Group?

MiMedx Group (NASDAQ:MDXG) and Biosig Technologies (NASDAQ:STEX) are both small-cap medical equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

MiMedx Group has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market. Comparatively, Biosig Technologies has a beta of 1.58, suggesting that its share price is 58% more volatile than the broader market.

MiMedx Group presently has a consensus target price of $8.50, indicating a potential upside of 133.20%. Biosig Technologies has a consensus target price of $8.00, indicating a potential upside of 499.25%. Given Biosig Technologies' higher probable upside, analysts clearly believe Biosig Technologies is more favorable than MiMedx Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Biosig Technologies had 3 more articles in the media than MiMedx Group. MarketBeat recorded 6 mentions for Biosig Technologies and 3 mentions for MiMedx Group. Biosig Technologies' average media sentiment score of 0.34 beat MiMedx Group's score of 0.22 indicating that Biosig Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biosig Technologies	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MiMedx Group has higher revenue and earnings than Biosig Technologies. Biosig Technologies is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$418.63M	1.30	$48.58M	$0.20	18.23
Biosig Technologies	N/A	N/A	-$462.77M	-$9.71	N/A

79.2% of MiMedx Group shares are held by institutional investors. Comparatively, 7.2% of Biosig Technologies shares are held by institutional investors. 2.5% of MiMedx Group shares are held by insiders. Comparatively, 52.7% of Biosig Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

MiMedx Group has a net margin of 7.88% compared to Biosig Technologies' net margin of 0.00%. MiMedx Group's return on equity of 21.03% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	7.88%	21.03%	15.92%
Biosig Technologies	N/A	-717.92%	-336.75%

Summary

MiMedx Group beats Biosig Technologies on 10 of the 15 factors compared between the two stocks.

How does Biosig Technologies compare to NeuroPace?

Biosig Technologies (NASDAQ:STEX) and NeuroPace (NASDAQ:NPCE) are both small-cap medical equipment companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

Biosig Technologies has a beta of 1.58, indicating that its share price is 58% more volatile than the broader market. Comparatively, NeuroPace has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market.

Biosig Technologies presently has a consensus target price of $8.00, suggesting a potential upside of 499.25%. NeuroPace has a consensus target price of $18.83, suggesting a potential upside of 12.36%. Given Biosig Technologies' higher possible upside, equities analysts clearly believe Biosig Technologies is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Biosig Technologies has a net margin of 0.00% compared to NeuroPace's net margin of -21.67%. NeuroPace's return on equity of -108.20% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	-717.92%	-336.75%
NeuroPace	-21.67%	-108.20%	-18.50%

7.2% of Biosig Technologies shares are owned by institutional investors. Comparatively, 78.8% of NeuroPace shares are owned by institutional investors. 52.7% of Biosig Technologies shares are owned by insiders. Comparatively, 20.5% of NeuroPace shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, NeuroPace had 5 more articles in the media than Biosig Technologies. MarketBeat recorded 11 mentions for NeuroPace and 6 mentions for Biosig Technologies. NeuroPace's average media sentiment score of 0.74 beat Biosig Technologies' score of 0.34 indicating that NeuroPace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biosig Technologies	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeuroPace	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NeuroPace has higher revenue and earnings than Biosig Technologies. NeuroPace is trading at a lower price-to-earnings ratio than Biosig Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	N/A	N/A	-$462.77M	-$9.71	N/A
NeuroPace	$99.99M	5.71	-$21.47M	-$0.65	N/A

Summary

NeuroPace beats Biosig Technologies on 12 of the 16 factors compared between the two stocks.

Get Biosig Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STEX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STEX vs. The Competition

Export

Metric	Biosig Technologies	Surgical, Medical, And Dental Instruments And Supplies Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$243.64M	$3.22B	$4.24B	$12.33B
Dividend Yield	N/A	N/A	6.21%	5.33%
P/E Ratio	-0.14	2.80	22.04	25.70
Price / Sales	N/A	32.29	122.92	99.36
Price / Cash	N/A	4.40	53.85	56.16
Price / Book	1.52	3.18	35.19	7.04
Net Income	-$462.77M	-$76.79M	$112.32M	$335.04M
7 Day Performance	39.25%	1.98%	1.49%	2.69%
1 Month Performance	30.88%	-5.04%	2.71%	1.49%
1 Year Performance	N/A	97.45%	16.07%	35.72%

Biosig Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STEX Biosig Technologies	2.2594 of 5 stars	$1.34 +18.1%	$8.00 +499.3%	N/A	$243.64M	N/A	N/A	50	News Coverage Analyst Forecast Insider Trade Gap Up
SIBN SiBone	2.3887 of 5 stars	$14.76 +4.2%	$23.00 +55.8%	-22.5%	$627.99M	$200.93M	N/A	350	Insider Trade
CBLL CeriBell	2.1654 of 5 stars	$16.58 +1.7%	$22.20 +33.9%	+6.8%	$618.47M	$89.06M	N/A	N/A
BWAY Brainsway	1.8108 of 5 stars	$14.88 -1.0%	$15.00 +0.8%	+190.0%	$601.76M	$52.22M	42.52	120
MDXG MiMedx Group	3.6845 of 5 stars	$3.59 +0.8%	$8.50 +136.8%	-47.7%	$530.25M	$418.63M	17.95	870

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:STEX) was last updated on 5/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biosig Technologies (STEX) Competitors

STEX vs. SIBN, CBLL, BWAY, MDXG, and NPCE

How does Biosig Technologies compare to SiBone?

Summary

How does Biosig Technologies compare to CeriBell?

Summary

How does Biosig Technologies compare to Brainsway?

Summary

How does Biosig Technologies compare to MiMedx Group?

Summary

How does Biosig Technologies compare to NeuroPace?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STEX vs. The Competition

Biosig Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biosig Technologies (STEX) Competitors

STEX vs. SIBN, CBLL, BWAY, MDXG, and NPCE

How does Biosig Technologies compare to SiBone?

Which has more risk & volatility, STEX or SIBN?

Which has higher valuation & earnings, STEX or SIBN?

Does the media refer more to STEX or SIBN?

Is STEX or SIBN more profitable?

Do insiders and institutionals have more ownership in STEX or SIBN?

Do analysts recommend STEX or SIBN?

Summary

How does Biosig Technologies compare to CeriBell?

Is STEX or CBLL more profitable?

Do analysts rate STEX or CBLL?

Which has higher earnings and valuation, STEX or CBLL?

Which has more volatility & risk, STEX or CBLL?

Does the media refer more to STEX or CBLL?

Do insiders and institutionals hold more shares of STEX or CBLL?

Summary

How does Biosig Technologies compare to Brainsway?

Which has more volatility and risk, STEX or BWAY?

Does the media favor STEX or BWAY?

Is STEX or BWAY more profitable?

Which has preferable valuation and earnings, STEX or BWAY?

Do analysts recommend STEX or BWAY?

Do insiders & institutionals believe in STEX or BWAY?

Summary

How does Biosig Technologies compare to MiMedx Group?

Which has more risk & volatility, MDXG or STEX?

Do analysts prefer MDXG or STEX?

Does the media refer more to MDXG or STEX?

Which has stronger earnings & valuation, MDXG or STEX?

Do insiders and institutionals believe in MDXG or STEX?

Is MDXG or STEX more profitable?

Summary

How does Biosig Technologies compare to NeuroPace?

Which has more volatility and risk, STEX or NPCE?

Do analysts recommend STEX or NPCE?

Is STEX or NPCE more profitable?

Do institutionals and insiders hold more shares of STEX or NPCE?

Does the media prefer STEX or NPCE?

Which has higher valuation and earnings, STEX or NPCE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STEX vs. The Competition

Biosig Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools